MRSA Detection at POC
ICHORtec's Quantum Leap in MRSA Detection at POC
In the shadow of “the pandemic behind the pandemic,” antimicrobial resistance (AMR) escalates unchecked, with superbugs like Methicillin-resistant Staphylococcus aureus (MRSA) fueling healthcare crises. Globally, bacterial AMR claimed 1.27 million lives directly in 2019, associating with nearly 5 million deaths and imposing staggering economic burdens, up to US$700 billion in hospital costs alone.
MRSA accelerated by antibiotic misuse and poor controls—threatens routine treatments, linking to healthcare-associated infections (HAIs) that affect 1 in 31 US patients daily. With 1 in 3 HAI bacteria resistant, outcomes worsen for vulnerable groups like cancer patients or those on dialysis. Traditional lab-bound methods like culture or PCR lag behind, delaying isolation and stewardship in high-risk settings.
Empower Your Frontline: ICHORtec's Q-FMB® Platform
Introducing ICHORtec’s Quantum Free Energy of Molecular Binding (Q-FMB®) technology in the portable ICHORscope, redefining MRSA screening with quantum leap at the point of care.
The ICHORscope: Compact power for instant MRSA insights, no lab required.
Target mecA and nuc genes for confident MRSA detection, minimizing false positives. Measure ΔG binding energy for single-nucleotide accuracy in under 5 minutes, even in inhibitor-rich samples. Closed cartridges eliminate contamination; UUID traceability integrates with cloud surveillance for outbreak alerts and stewardship.
Core Benefits
- Speed: Results in 5 minutes for swift triage.
- Accuracy: 100% analytical precision in validations; ISO 13485/GCLP compliant.
- Portability: Lab-free design for EDs, clinics, and wards.
- Connectivity: Bluetooth exports, real-time dashboards for proactive control.
Seamless Workflow, Transformative Impact
Swab, load cartridge, analyze via Q-FMB®, view “positive/negative” with controls. Secure data flows to clouds for analytics—enabling same-day isolation, targeted therapy, and HAI prevention.
Regulatory Status
The Q-FMB® and ICHORscope platform are progressing through the regulatory pathway toward WHO prequalification and international diagnostic approval. ICHORtec is collaborating with leading global research centers to complete the clinical validation phase. During this period, Q-FMB® systems are available as Research Use Only (RUO) products under the ICHORtec Research Framework, aligned with ISO 13485 and GCLP standards.